

Subject Index

- Abelson leukemia virus 7, 384, 467
 - , bone marrow cultures 272
 - , target cells 468
- Adipocytes 278
- ADP Ribosylation 225
- Adriamycin see also chemotherapy
 - in AML 39, 46, 54
- Agar colony technique 237, 251
- ALL see also leukemia
 - , cellmembran antigen in 326
 - , CFU-C in 239, 243, 246, 251, 256
 - , natural killer cells 351
 - , relaps in 95, 114
 - , treatment of 77, 79, 88, 91, 100, 108
- Alpha-naphthylacetate-esterase in blood cells 268
 - in bone marrow cultures 277, 291
 - in Reed-Sternberg cells 12
 - in T- cell lines 505
- AML
 - , antiserum 334
 - , cellmembran antigen in 332
 - , CFU-C in 239, 243, 246, 251
 - , continuous cell line of 517
 - , CSF in 239, 243
 - , immunotherapy in 39, 55
 - , meningeal leukemia in 51
 - , remission of 40, 55
 - , surface immunoglobulins in 340
 - , treatment of 38, 54
- ANLL
 - , treatment with low dose cytosine arabinoside 59
 - , natural killer cells in 351
- Anthracycline, treatment with 38, 45
- Antibodies
 - , for GvHD supression in bone marrow transplan-
tation 126, 132
 - , idiotypic 343, 368
 - , monoclonal 548
 - , secreting cells, viral expression in 365
 - , to BLV 498
 - , to FLV 485, 492
 - , to FOCMA 484, 488, 492
 - , to HLA 300, 310
 - , to mouse brain 306
 - , to T cells 124
- Antigen
 - , common ALL (c ALL) 265, 326
 - , C-typ viral proteins in human leukemia 527, 530
 - , human leucocyte 309
 - , leukemic 332
 - , T- cell 266
 - , transformation specific 485, 521
 - , tumor 378, 485
- Anti-idiotypic immunity 343, 368
 - , progressiv tumor growth stimulated by 371
- Asparaginase see also chemotherapy
 - , treatment with 54
- Ataxia telangiectasia, chromosom 14 anomalia in 5,
181
- Avian
 - , erythroblastosis virus (AEV) 417
 - , gene products of 397
 - , leukosis viruses 417, 432, 439, 445, 452
 - , myeloblastosis genom 429
 - , myelocytomatosis virus 418
 - , sarcoma virus 397, 405, 409
 - , target cells for 419
 - , transformation of hematopoietic cells by 418
 - , transforming gen product of 397
- Bacterial binding to lymphocytes 356
 - , to leukemic cells 358
- BALB/c mouse 479
- B-cells see lymphocytes and lymphoma
- BFM study group 87
- BFUE 301
- Blast colony forming cells, recloning of 248
- B-lymphocytes 179, 191, 314
 - , differentiation 318
 - , lymphoma 3, 191, 315, 439
- Bone-marrow
 - , culture 243, 246, 252, 255
 - , continuous 272, 276, 289
 - , transplantation 132, 136
 - , treatment with ATCG in 133
- Bovine leukemia 495, 498
 - , antibody response to 499
 - , genom of 496

- Bovine leukemia
 - , proteins of 499
 - , provirus of 495
 - , virus 495, 498
- Bromodeoxyuridine, effect on endogenous retrovirus production 365
- Burkitt lymphoma 3
 - , chromosomal changes in 4, 31, 179, 192

- Carcinogen 5, 9, 393
- Cat leukemia see FLV
- Cell culture 276, see also cell lines
- Cell differentiation 548
 - , block of 215
 - , cellmembran antigens in 265, 296, 311
 - , expression of lysozyme gene in 177
 - , glycophorin A in 305
 - , induction of 216
 - , of leukemic cells 261, 265, 268
 - , viral expression in 366
- Cell fusion 527
 - , induced by EBV 193
- Cell hybrids, production of monoclonal antibodies in 294
- Cell line
 - , DAUDI 180
 - , HL-60 215
 - , Hodgkin 232
 - , human Teratocarcinom 541
 - , K 562 339
 - , leukemia lymphoma 323
 - , metastasing tumor 378
 - , murine myelomonocytic (WEHI-3) 238
 - , Ragi 182
 - , Reh 265
 - , T-cell neoplasias 505
 - , U-937 215
 - , WEHI-3 238, 273
- Cell-mediated immunity in X-linked lymphoproliferative syndrome 207
- Cell membrane see cell surface
- Cell surface antigen
 - , bacteria as markers for 355
 - in ALL 265
 - in AML 334
 - in bloodcell differentiation 215, 265, 301, 305, 310, 340
 - in leukemia 340
 - , monoclonal antibodies against 294, 310
 - , receptor in leukemogenesis 360
- Cell transformation 397
- CFU
 - C 239, 277, 291, 305
 - E 301
 - GEMM 247
 - GM
 - , inhibition by Ferritin 244
 - by LIA 243
 - S 305
- Chemoimmunotherapy of AML 39, 140
- Chemotherapy
 - , combination 39, 45, 53, 79, 88, 91, 100, 108, 116, 122, 547
 - , cytoreduction under 73
 - , drug sensitivity in 55
 - in vitro test for 56
 - , for relaps 95, 112
- Childrens Cancer study group 77, 84
- Chromosomes abnormalities
 - in atraxia telangiectasia 181
 - in Burkitt lymphoma 180
 - in leukemia 27, 161
 - in lymphoreticularneoplasias 5, 161
 - in human malignancies 160, 162
 - in malignant transformation 151
 - and myeloid differentiation 8
 - and viral onc genes 392
 - , banding technique 151
 - , flow sorting 156
 - , gene mapping of 156
 - , nucleolar organizing region of 152
- Clonal, origin of tumor 447
- Cloning cells 294
 - , molecular 474
- CML, chromosom abberation in 164
 - , diffusions chamber culture in 262
- CNS-leukemia 104
 - , prophylaxis of 95, 122
- Cocultivation 527
- Common ALL antigen 296
 - in bone marrow cells 299, 326
 - in serum of leukemia patients 330
 - , preparation of 296, 326
- Computer tomography after intra theleal therapy 105
- Contignity theory in Hodgkin's disease 15
- Corticosteroids in bone marrow cultures 278, 291
- Cox regression analysis 80, 90
- CSF 237
 - , independent colony forming cells 272
 - , production in WEHI-3 cells 238
- C-type virus see viral and virus
- Cyclophosphamide see chemotherapy
- Cytochemistry in ALL 268
 - in plasma clot cultures 255
 - in T-cell lines 505
- Cytosine arabinosid see chemotherapy
 - , treatment of ANLL with low dose 59
- Cytotoxicity 346, 351, see also T-cells

- DAUDI cell line 180
- Daunorubicine see chemotherapy
- Diffusion chamber, differentiation of leukemic cells in 62, 262, 265
- Dihydrofolate reductase gene 167, 171
 - , transformation of human HCT-8 cells by 171
- Dimethylbenz(a)anthracene, T-cell leukemia induced by 5

- Dimethylsulfoxide (DMSO), differentiation of human leukemic cells by 215, 268
- DNA fragments 479, 496
- , expression 201
- , mediated gene transfer 171
- , methylation and gene
- , RNA hybridization 515, 517
- , tumor virus 447, 497, 548
- , viral 197, 383, 497
- Double minutes 153

- EBNA 3**, 184
- ELISA 530
- Epigenetic, control in tumorigenicity 8
- Episomes, viral DNA in 198
- Epstein-Barr virus 3, 179, 207, 548
- , antibodies against 192, 208
- , Buskitt lymphoma 3, 179, 191
- , cell fusion with 193
- , genom 191
- , infected cells 192
- , mononucleosis infectiosa 4, 179, 191, 207
- , nasopharyngeal carcinoma 179, 191
- , receptor 180
- , Virus Capsid Antigen of 192
- , X-linked malignant lymphoma 207
- Erythrocyte ghosts, loaded with EBNA 185
- , used for microinjection 143, 185
- , used for therapy 143

- FeLV/FeSV** 384, 483, 488, 492
- , anti-sera 492
- , viral nonproducer 492
- Flow cytometry of chromosomes 156
- FOCMA 484, 488, 492
- , immune response to 485, 490, 492
- Friend leukemia virus in haemopoiesis 272, 472
- Fujinami sarcoma virus 389
- Fusion injection technique 143

- Gag** see also gene
- , gene 386
- x polyproteins 485, 488
- Gene**
- , aev 389
- , amplification 153
- , amv 430
- , carcino 5, 9, 393
- , DHFR- 172
- , drug resistance 167
- , EBV see EBV
- , env 386, 455
- , episomal viral 197
- , expression and DNA methylation 201
- , fev 389
- , gag 386
- -globin 157
- , insertion 167
- , integration 172
- , lysozyme 175
- , mal 460
- , mcv 389
- , mos 460
- , onc 386, 455, 482
- , pol 386, 455
- , retrovirus 383
- , src 385
- , transforming 168, 171, 383, 441
- Genetic, control in tumorigenicity 8
- , elements 152
- , influence on myelopoiesis 237
- , of leukemogenesis 432
- , structures of viruses 386
- , traits 152
- Genom see also gene
- , AMV 430
- , BALB/c 479
- , SFFV 472
- , virus 433
- Glycophorin A 300, 338
- in erythroid differentiation 301, 340
- in leukemic cells 340
- , structur 238
- Graft versus host disease 124, 137, 140
- , pretreatment with antisera 124
- , suppression of 124
- Growth-control of T-cell 363, 504
- , T-lymphomas 363, 504
- -factor dependent blood cell lines 273
- -inhibition by monoclonal antibodies 364
- , U₃ region for 433

- Hematopoietic**
- , differentiation 325
- and virus 272
- , glycophorin A in 339
- , progenitors 246
- , regulation of 272
- , target cells 417
- Herpes virus 197
- , DNA-sequences in lymphoid tumor cell lines 198
- Heterogeneous nuclear RNA 517
- in leukemia 518
- HLA-ABC in erythropoietic cells 301
- -DR in leukemic cells 300
- in erythropoietic cells 301, 340
- , monoclonal antibodies against 300, 310
- HL60-promyelocytic cells 517
- Hodgkin's disease 11
- , immunological defect in 16
- , long term cultures of 229
- Homogeneously staining regions 153
- Human T-cell lymphoma leukemia virus (HTLV) 509

- Human T- cell
 - , characterization by nucleic acid hybridization 515
- Hybrid cells 181
- Hyperthermia, treatment with 146

- Ia-antigen 297
 - , expression on Hodgkin cell lines 213
 - , U-937 cell-surface 219
 - in lymphoid cell differentiation 180
- Idiotypic-antibodies 343
- Immune response
 - , against antigen loaded erythrocytes ghost 144
 - in Hodgkin's disease 17
 - in X-linked lymphoproliferative syndrome 210
 - , to FOCMA 485
- Immune system
 - , adaption to tumor cells 378
 - , cloning cells of 294
 - , idiotypic compartments 343
 - , network concept of 343
- Immunotherapy of AML 39, 54
 - , nonspecific 343
- Initiation factor in protein synthesis 147
- Insertion of genes 167
- Interferon, activated lymphocytes 346
 - , effect of translation 148
 - , treatment of leukemia 63
- Iron, apoferritin in Hodgkin's disease 20
 - , binding proteins 20, 244
 - , ferritin inhibition activity on CFU-MG 244
- Isoenzyme in lymphomas 222

- Karyotype 151
 - in leukemia 27
 - in nasopharyngeal carcinomas 195
- Killer cells 346, 351
 - , isolation by bacteria binding 358

- Lactoferrin, inhibition of CSF production by 244
- Lectin induced cell killing 362
- Leukemia
 - , ADP-ribosylation in 226
 - , associated inhibitory activity (LIA) 242
 - , bovine 495
 - , cell markers in 355
 - , CFU-C in 243, 246, 252, 255
 - , chromosom abnormalities in 27, 161
 - , CNS 104
 - , cytoreduction 73
 - , diffusion chamber culture in 62, 262, 265
 - , feline 483
 - , genetic factors 237
 - , hn RNA in 517
 - , human, oncoviruses in 502, 527, 530
 - , infections 483, 495, 512
 - , interferon treatment of 63
 - in vitro induction of 272
 - , killer cells in 351
 - , meningeal 51, 81
 - , network concept in 343
 - , prognostic factor in 78, 89
 - , radiation induced 537
 - , T-cell 5, 70, 90, 506
 - , terminale deoxynucleotidyl transferase in 69
 - , treatment of 2, 22, 53, 79, 88, 91, 100, 108, 116
 - , treatment with bone marrow transplantation 132, 136, 140
 - , with high dose thymidin 73
 - , viruses 390, 409, 455
 - , virus negative 492
- Leukemic cell
 - , antigens, related to C-typ viruses see viral and virus
 - , cALL-antigen expression in see commonALL-antigen
 - , differentiation of, in culture 62, 262, 265, 268
 - , drug sensitivity of 55
 - , killer cells against 348
 - , lines see cell lines
 - , surface marker of 298, 355
- Leukemogenesis, mechanism of 272
 - , genetics of 432
 - , promoter insertion model for 444
 - , retrovirus in 445, 512
 - , U₃-region in 435
- Long terminal repeat 458, 460
- LPS see also lectin
 - , stimulated lymphocyt cultures 366
- Lymphangiogram in Hodgkin's disease 16
- Lymphocytes see also B- and T-lymphocytes
 - , antiidiotypic 343
 - , bacteria binding to 355
 - , T- 343
- Lymphomas
 - , cell lines 198, 323, 377, 505
 - , histological types of 318
 - , immunological subtypes of 315
 - , isoenzymes in 222
 - , pathogenesis of 372
 - , T-cell 502
 - , TDT-activities in 69
- Lymphoreticular neoplasias 14q⁺ markers in 4, 31
- Lymphotoxicity 345
- Lysozyme gene 175
 - , expression in macrophages 176
 - in Oviduct 176

- Macrophage, expression of lysozyme gene in 176
 - , isoenzyme in 222
 - , regulation of myelopoiesis by 238
 - , synthesis of CSF- and PGE by 239
- Meningeal leukemia 51
- Methotrexate see also chemotherapy

- Methotrexate
 - , intermediate dose of 99
 - , resistant dihydrofolate reductase 167
 - , treatment with 47
- Methylation of DNA 201
 - , of viral DNA 199
- Methylnitrosourea, induction of leukemia in culture 273
- Microinjection, intracellular 143
- Moloney murine sarcoma virus (MSV), cloned fragments 462
- Monoclonal antibodies 179, 294, 296, 309, 360, 548
 - , against hemopoietic precursor cells 296, 310
 - , OKT 297, 311
- Mononucleosis infectiosa, EBV in 4, 179, 191
 - , killer cells in 347
- Murine leukemia virus, fibroblast transformation 479
 - , surface receptors for 360, 363
- Mutation in malignancy 163
- Mycosis fungoides 502, 515
- Myeloid differentiation, expression of lysozyme gene in 177
 - , dysplasia 34
 - , chromosome determinants in 8
 - , TDT in 76
- Myeloperoxidase 256
 - in bone marrow cultures 277, 291
 - in plasma clot cultures 256
- Myelopoiesis, genetic and oncogenic influences 237
 - , inhibition of 238
 - , regulation of 241

- Nasopharyngeal carcinoma 179
 - , EBV in 192
 - , karyotypes of 195
- Natural killing 345
 - , cells 351
- Nephroblastomas, virus induced 452
- Network concept 343
- Nude mice, Hodgkin cell lines in 232

- OKT series of monoclonal 297, 311
- Oncogen 387, see also gene
 - , designs 390
- Oncogenetic influences on myelopoiesis 237
- Oncorna virus in human leukemia 502, 527
- Osteosarcoma, virus induced 452

- Papovavirus 3
 - , B-lymphotropic 204
- Philadelphia chromosome in leukemia 27, 164
- Phosphoproteins 524
 - , gag related 389
- Phosphorylation 397
 - , gag related 389
 - in protein synthesis 148, 414
 - , of initial factor 147
 - , phosphoproteins 524
- Plasma clot cultures 255
- pp60^{src} 397, 402, 405, 411
- Precursor polypeptides 524
- Prednisolone, treatment with 47
- Preleukemia, histopathology of 34
 - , induction in bone marrow culture 274
 - , ph¹-chromosom in 37
- Prognostic factors in leukemia 78, 82, 90, 112, 118, 121
- Promoter, insertion model for leukemogenesis 444
 - , tumor 201
- Prostaglandines, effect of leukemia cell differentiation 270
 - , inhibition of CFU-C proliferation by 238
 - , production of 239
- Protein kinase 398, 402, 405, 414
 - , of the HS-HL system 147
 - in leukemic cells 225
- Protein synthesis, control of 414
 - , inhibition by HS, HL-heme 148
 - , by interferon-ds RNA 148
 - , initiation factor in 146, 414
- Provirus, moloney sarcoma (-mos) 460

- Radiation, induced murine leukemia 538
- Raji-cell line 182
- Recombinants of viruses 435, 457
- Read-Sternberg cell 12, 229
 - , cytochemistry of 13, 232
- Relaps in childhood leukemia 94, 101, 114, 121
 - , CNS 81, 101, 119, 121
 - in T-cell leukemia 122
 - , leukemic 94
 - , testicular 81, 114, 119, 121
 - , therapy of 95, 112
- Remission in AML 40, 47, 140
 - , after bone marrow transplantation 140
 - , cause of death in 109
 - , CFU-C in 252, 256
 - in childhood leukemia 81, 90, 96, 103, 111, 117, 122
 - in T-cell leukemia 122
- Restriction analysis 430
 - , of SFFV-DNA 475
 - , of tumor DNA 441, 446, 496
- Retrovirus 383, 547
 - , endogenes 537
 - , genes in thymic nurse cells 374
 - in human teratocarcinoma cell lines 541
- Reverse transcriptase in thymic epithelial cells 374
 - in human T-cell leukemia virus 509
 - in thymic epithelial cells 374
- Risk index in leukemia 82, 89, 101, 118
- RNA, heterogeneous 517

- RNA
 –, of tumor virus 439
 Rous sarcoma virus 383, 402
- Sarcoma virus 384, see also virus
 Sezary syndrome 502
 Simian sarcoma virus 409, 520, 524
 ----, non producer cells 520, 524
 ----, p30 positiv immunreaction in human leukemia 528, 530
 ----, protein 411
 ----, transformation specific glycoprotein 521
 6-Mercaptopurine see chemotherapy
 6-Thioguanine see also chemotherapy
 –, treatment in AML 54
 Src-gene 385, 402
 Suppressor cell in Hodgkin's disease 19
 Surface markers in Hodgkin cell lines 231
 -- in leukemia lymphoma cell lines 324, 456
 -- in U-937 cells 218
 Susceptibility theory of Hodgkin's disease 15
- Target cells for AEV 419
 --, for transformation 455, 468
 --, hemopoietic 417
 T-cell
 –, alloreactive 320
 –, antigen 297, 311
 –, anti-human globulin against 129
 –, clones see hybridomas
 –, culture 301, 507
 –, cytotoxic 321, 343, 346, 377
 –, differentiation 372
 –, growth factor 70, 294, 320, 343, 503
 –, helper 294, 320
 –, hybridomas 294, 320, 360
 – in Hodgkin disease 19
 –, leukemia 5, 70, 90, 122, 505, 515
 –, line 505
 –, to HLA-antigenes 311
 –, trisomy in 15
 Teratocarcinoma 8
 –, retrovirus in human 541
 Terminal deocynucleotidyl transterase in leukemia 68, 296
 – and response to therapy 71
 – in lymphomas 69
 – in normal tissues 296
 – in T-cell differentiation 311, 503
 Thymic, lymphomas 360
 –, nurse cells 372
 --, expression of retroviral determinants in 374
 Thymidin, high dose therapy in leukemia 75
 Transfection, with subgenomic DNA fragments 462
 Transformation
 –, chromosomes in see chromosomes
 –, of bone marrow cells 168
 –, of fibroblasts 479
 –, of human HCI-8 cells 171
 –, specific antigens 485, 521
 –, subgenomic fragments induced 461, 476
 –, target cells for 455, 467
 –, virus induced 384, 417
 Transforming gene 168, 171, 383, 441
 --, activity of cloned MSV fragments 462
 --, products 397
 --, proteins 391
 Translation of viral RNA 389
 ----, limited by interferron 148
 ----, by hyperthermia 148
 Translocation 151
 –, for ph¹-chromosomes 28
 – in CMC 164
 – in myeloblastic leukemia 30
 Transplantation of bone marrow 132, 136, 140
 ----, prevention of GvHD by T-cell anti sera 132
 – in leukemia 132, 136, 140
 Transposable genetic elements 152
 Treatment see also chemotherapy and leukemia
 –, of ALL 79, 88, 91, 100, 108, 116
 –, of AML (ANLL) 2, 22, 53
 –, of T-cell leukemia 122
 –, with drug loaded erythrocyts ghosts 143
 –, with immunotherapy 139, 343
 –, with transplantation 132, 136
 Trisomy 7 in lymphoma cell lines 180
 –, 15 in T-cell leukemogenesis 6
 Tumor cell
 --, associated transplantation antigens 377
 --, clonal origin 447
 --, evolution 9
 --, growth, stimulated by anti-idiotypic lymphocytes 368
 --, immunoadaption of 378
 --, metastasis 368, 377
 --, specific DNA 446
 Tupaia, bone marrow cultures 281
 12-Tetra-decanoyl-phorbol-13-acetate (TPA), differentiation of human leukemic cells by 315
- U₃-region in growth 433
 – in leukemogenesis 435
 U-937 cell line 215
- VAPA¹⁰ treatment of AML with 45
 Vincristine see also chemotherapy
 –, treatment with in AML 39, 47, 54
 Viral see also virus
 –, antigens 184, 230
 -- in human leukemia 527, 530
 -- in humoral immune response 485, 492
 –, DNA 198
 --, restriction analysis of 441, 446, 496
 –, expression in differentiating lymphocytes 366

Viral
-, genes 462 see also gene
-, genome 197, 433, 444
-, proteins in human leukemia 527, 530
-, RNA 439, 515, 517
--, translation of 148
Virus see also viral
-, AEV 384, 418
-, AMV 418
-, avian tumor 386
-, endogen 435, 537
--, expression in lymphocytes 366
-, exogen 435
-, HTLV 507, 515

-, MC 29, 384, 409, 418
-, sarcoma 384
-, SFFV 472

Waldeyer's ring, EBV-linked carcinoma in 192
WEHI-3 cell line 238, 273

X-linked lymphoproliferative syndrom 207
---, EBV infection in 207
---, immunopathology of 210

Haematology and Blood Transfusion

Supplement volumes to the
journal „Blut“

Editors: H. Heimpel,
D. Huhn, G. Ruhenstroth-
Bauer, W. Stich

Aplastic Anemia

Pathophysiology and Approaches to Therapy
International Symposium on Aplastic Anemia
July 19–22, 1978, Schloß Reisenburg
Editors: H. Heimpel, E. C. Gordon-Smith, W. Heit,
B. Kubanek
1979. 81 figures, 71 tables. XIII, 292 pages (Volume 24)
ISBN 3-540-09772-4

Immunobiology of Bone Marrow Transplantation

International Seminar, March 8–10, 1979, Neuherberg/
München
Editors: S. Thierfelder, H. Rodt, H. J. Kolb
1980. 123 figures, 123 tables. XV, 430 pages (Volume 25)
ISBN 3-540-09405-9

Immunological Diagnosis of Leukemias and Lymphomas

International Symposium of the Institut für Hämatologie,
GSF, October 28–30, 1976, Neuherberg/München
Editors: S. Thierfelder, H. Rodt, E. Thiel
1977. 98 figures, 2 in color, 101 tables. X, 387 pages
(Volume 20)
ISBN 3-540-08216-6

Modern Trends in Human Leukemia II

Biological, Immunological, Therapeutical and Virological
Aspects
Editors: R. Neth, R. C. Gallo, K. Mannweiler, W. C. Moloney
1976. 150 figures, 141 tables. XI, 576 pages. (Volume 19)
ISBN 3-540-79785-8

Modern Trends in Human Leukemia III

Newest Results in Clinical and Biological Research
9th Scientific Meeting of „Gesellschaft Deutscher Natur-
forscher und Ärzte“
Together with the “Deutsche Gesellschaft für Hämatologie“
Wilsede, June 19–23, 1978
Editors: R. Neth, R. C. Gallo, P.-H. Hofschneider,
K. Mannweiler
1979. 171 figures, 128 tables. XXII, 599 pages. (Volume 23)
ISBN 3-540-08999-3



Springer-Verlag
Berlin
Heidelberg
New York

Automation in Hematology

What to Measure and Why

Editors: D. W. Ross, G. Brecher, M. C. Bessis

1980. 106 figures, 45 tables. VIII, 338 pages

(Monograph edition of the international journal *Blood Cells*,
Vol. 6, 2-3) ISBN 3-540-10225-6

J. C. Cawley, G. F. Burns, F. G. J. Hayhoe

Hairy-Cell Leukemia

1980. 64 figures, 4 tables. IX, 123 pages

(Recent Results in Cancer Research, Vol. 72)

ISBN 3-540-09920-4

Fundamentals of Immunology

By O. G. Bier, W. Dias Da Silva, D. Götze, I. Mota

Revised for the English edition by D. Götze

1981. 168 figures, approx. 73 tables. Approx. 460 pages

ISBN 3-540-90529-4

Immunodiagnosis and Immunotherapy of Malignant Tumors

Relevance to Surgery

Editors: H.-D. Flad, C. Herfarth, M. Betzler

1979. 101 figures, 109 tables. X, 329 pages

ISBN 3-540-09161-0

Immunostimulation

Editors: L. Chedid, P. A. Miescher, H. J. Mueller-Eberhard

1980. 44 figures, 39 tables. VIII, 236 pages

(Monograph edition of the international journal *Springer*

Series in Immunopathology, Vol. 2, 1-2) ISBN 3-540-10354-6

K. Lennert

Histopathology of Non-Hodgkin's Lymphomas

(Based on the Kiel-Classification)

In collaboration with H. Stein

Translation from the German by M. Soehring, A. G. Stansfeld

1981. 68 figures (some in color), 5 tables. Approx. 130 pages

ISBN 3-540-10445-3

Preleukemia

Editors: F. Schmalzl, K.-P. Hellriegel

1979. 64 figures, 56 tables. XII, 194 pages

ISBN 3-540-09698-1

Strategies in Clinical Hematology

Editors: R. Gross, K. P. Hellriegel

1979. 22 figures, 33 tables. X, 140 pages

(Recent Results in Cancer Research, Vol. 69)

ISBN 3-540-09578-0



Springer-Verlag
Berlin
Heidelberg
New York